2547
ARDS has been associated with the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines.
 ( adverse event: associated ,  ARDS: Effect, the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and OKT3: Treatment, infliximab: Treatment.Drug, gemtuzumab: Treatment.Drug, ozogamicin: Treatment.Drug, OKT3: Treatment.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( adverse event: associated ,  ARDS: Effect, the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and OKT3: Treatment, infliximab: Treatment.Drug, gemtuzumab: Treatment.Drug, ozogamicin: Treatment.Drug, OKT3: Treatment.Drug) 